ライフサイエンスコーパス: nicotine dependence

1 type, inhalation depth, Fagerstrom-assessed nicotine dependence).

2 , placebo-controlled trials of naltrexone in nicotine dependence.

3 receptor (nAChR) influence both ethanol and nicotine dependence.

4 s a critical relay circuit in the control of nicotine dependence.

5 onset of regular smoking predicted level of nicotine dependence.

6 appear to be involved in the later stages of nicotine dependence.

7 ning processes contribute to the etiology of nicotine dependence.

8 and is thought to be a critical component of nicotine dependence.

9 tinic receptor variants that affect risk for nicotine dependence.

10 RNA6-CHRNB3 gene clusters that contribute to nicotine dependence.

11 associated with comorbid cocaine, opium, and nicotine dependence.

12 istical Manual (fourth edition) diagnosis of nicotine dependence.

13 associated with a protective effect against nicotine dependence.

14 al molecular component in the development of nicotine dependence.

15 disorders including Parkinson's disease and nicotine dependence.

16 and controls to test for an association with nicotine dependence.

17 tine dependence with the Fagerstrom Test for Nicotine Dependence.

18 ghlighted in previous studies of smoking and nicotine dependence.

19 be new pharmacotherapeutics for treatment of nicotine dependence.

20 obiology, genetic etiology, and treatment of nicotine dependence.

21 CHRNA3-CHRNB4) and both smoking quantity and nicotine dependence.

22 TA DA neuronal function, DA transmission and nicotine dependence.

23 rug reinforcement and has been implicated in nicotine dependence.

24 riant, but not the N variant associated with nicotine dependence.

25 nes (i.e., TAS2R16 and TAS2R38) in affecting nicotine dependence.

26 lele association with smoking initiation and nicotine dependence.

27 ntrolled for, with the possible exception of nicotine dependence.

28 o and number of cigarettes smoked per day or nicotine dependence.

29 nabis dependence; the second, on alcohol and nicotine dependence.

30 have been implicated in various measures of nicotine dependence.

31 tanding of the genetic mechanisms underlying nicotine dependence.

32 as measured by using the Fagerstrom Test for Nicotine Dependence.

33 dly linked to addictive disorders, including nicotine dependence.

34 ors (nAChRs) play a role in both alcohol and nicotine dependence.

35 s that can be long lasting and contribute to nicotine dependence.

36 ted in behavioural responses to nicotine and nicotine dependence.

37 ors contribute in part to the development of nicotine dependence.

38 nce to nervous system function, disease, and nicotine dependence.

39 CHRNA4 and tested them for association with nicotine dependence.

40 files associated with alcohol, cannabis, and nicotine dependence.

41 HRNB4 gene cluster and smoking heaviness and nicotine dependence.

42 m function, some of which must contribute to nicotine dependence.

43 g toward elucidating the basic mechanisms of nicotine dependence.

44 ain dopamine D2-type autoreceptors influence nicotine dependence.

45 lung cancer patients treated clinically for nicotine dependence.

46 onal Diagnostic Interview was used to assess nicotine dependence.

47 r, little is known about the epidemiology of nicotine dependence.

48 ighly effective treatment for the problem of nicotine dependence.

49 cts and are in danger of developing lifelong nicotine dependence.

50 is that may contribute to the development of nicotine dependence.

51 raduates are not adequately trained to treat nicotine dependence.

52 of new treatments for both schizophrenia and nicotine dependence.

53 as well as lifetime risk for alcoholism and nicotine dependence.

54 le is known about the role of this system in nicotine dependence.

55 an hormones on the etiology and treatment of nicotine dependence.

56 ntrol animals, suggesting a role for NRG3 in nicotine dependence.

57 CI, 52%-89%) and 98% (95% CI, 95%-100%) for nicotine dependence.

58 tress disorder; other anxiety disorders; and nicotine dependence.

59 ing, including use of medicines to help with nicotine dependence.

60 rbB4 signaling may be an important factor in nicotine dependence.

61 nificantly reduced cigarette consumption and nicotine dependence.

62 mokers and for smokers with a high degree of nicotine dependence.

63 ts for the treatment of comorbid alcohol and nicotine dependence.

64 ognitive/affective alterations that underlie nicotine dependence.

65 the pharmacotherapy of Parkinson disease and nicotine dependence.

66 s associated with an elevated risk for later nicotine dependence.

67 e exposure directly increases level of later nicotine dependence.

68 ence syndrome they were 1.72 (1.57-1.87) for nicotine dependence, 2.67 (2.38-2.99) for cannabis depen

69 rsion disorder (5.3%; 95% CI, 4.3% to 6.2%), nicotine dependence (4.5%; 95% CI, 3.6% to 5.4%), alcoho

70 s the most significantly associated SNP with nicotine dependence across five independent cohorts (tot

71 Results indicate that a history of nicotine dependence affects subsequent nicotine- but not

72 mia nervosa), and four were "externalizing" (nicotine dependence, alcohol dependence, drug abuse or d

73 anxiety disorder; suicidal ideation/attempt; nicotine dependence; alcohol abuse/dependence; and illic

74 ne self-administration and initial stages of nicotine dependence, alpha7 homomeric nAChRs appear to b

75 the CHRNA5-CHRNA3-CHRNB4 region that predict nicotine dependence also predicted a later age at smokin

76 ancy is associated with an increased risk of nicotine dependence among adult offspring.

77 re independently associated with smoking and nicotine dependence among cigarette smokers, using 1990-

78 sion subside, as indicated by high levels of nicotine dependence among individuals with remitted depr

79 ng pregnancy is a risk factor for subsequent nicotine dependence among offspring.

80 t increase the risks of both lung cancer and nicotine dependence and associated smoking behavior.

81 is available on the co-occurrence of DSM-IV nicotine dependence and Axis I and II psychiatric disord

82 Nicotine dependence and cocaine abuse are major public h

83 Nicotine dependence and cocaine abuse are major public h

84 tify a novel regulatory SNP association with nicotine dependence and connect, for the first time, pre

85 l data showed the genetic pleiotropy between nicotine dependence and COPD or lung function.

86 data show an increased risk for the onset of nicotine dependence and drug abuse or dependence in pers

87 nes that were reported to be associated with nicotine dependence and found significant joint action b

88 3239-rs12720071-rs806368 was associated with nicotine dependence and FTND score in the 2 samples (P <

89 -1 gene dysfunctions have been implicated in nicotine dependence and in autism spectrum disorders.

90 erest because of its apparent involvement in nicotine dependence and in the control of dopamine relea

91 thought to influence both susceptibility to nicotine dependence and its comorbid behavioral traits i

92 ence was measured by the Fagerstrom test for nicotine dependence and level of craving.

93 linked to smoking-related behaviors such as nicotine dependence and level of smoking.

94 ith recent reports of NRXN3 association with nicotine dependence and linkage with opiate dependence,

95 low mRNA expression of CHRNA5, the risk for nicotine dependence and lung cancer is significantly low

96 ine receptors (AChRs) that increases risk of nicotine dependence and lung cancer.

97 at are associated with an increased risk for nicotine dependence and lung cancer.

98 two distinct mechanisms conferring risk for nicotine dependence and lung cancer: altered receptor fu

99 type has recently been genetically linked to nicotine dependence and lung cancer; however, the mode o

100 al clinical applications in the treatment of nicotine dependence and many neuropsychiatric conditions

101 n of the CRF-CRF(1) system may contribute to nicotine dependence and may represent a prominent target

102 t may be beneficial in the treatment of both nicotine dependence and MDD.

103 New therapies for treating nicotine dependence and measures to liberalize access to

104 rface expression levels are modulated during nicotine dependence and multiple disorders of the nervou

105 disorders, and individuals who have comorbid nicotine dependence and other psychiatric disorders.

106 et for the discovery of novel medication for nicotine dependence and other substance-related disorder

107 insula plays a critical role in maintaining nicotine dependence and reactivity to smoking cues.

108 use, and rs6495309 has been associated with nicotine dependence and risk for lung cancer.

109 bipolar disorder, major depressive disorder, nicotine dependence and schizophrenia).

110 -level understanding of the insula's role in nicotine dependence and shows a relationship between inh

111 Striatal BPND was correlated negatively with nicotine dependence and smoking exposure.

112 Combining genetic and mechanistic studies of nicotine dependence and smoking heaviness may reveal nov

113 A5-CHRNA3-CHRNB4) previously associated with nicotine dependence and smoking quantity traits.

114 Associations between nicotine dependence and specific Axis I and II disorders

115 To independently assess the effects of nicotine dependence and stimulation of the nicotinic ace

116 and in relationships between midbrain BPND, nicotine dependence and striatal dopamine D2-type recept

117 GluR5 is a pathogenetic mechanism underlying nicotine dependence and the high relapse rate in individ

118 In this largest-ever GWAS meta-analysis for nicotine dependence and the largest-ever cross-ancestry

119 pharmacological therapies to aid in treating nicotine dependence and to improve smoking cessation suc

120 Nicotine dependence and veteran-reported physician-diagn

121 SNPs in EGLN2 are also associated with nicotine dependence and with smoking efficiency (CO/CPD)

122 ion, echoing the increased susceptibility to nicotine dependence and withdrawal noted for adolescent

123 le provides an overview of recent studies of nicotine dependence and withdrawal that used genetically

124 ove our understanding of the neurobiology of nicotine dependence and withdrawal.

125 ing, nicotine dependence (Fagerstrom Test of Nicotine Dependence), and cessation difficulties were ev

126 ed initiation of all types of substance use, nicotine dependence, and cannabis abuse/dependence (for

127 ture phenotypes of persistent heavy smoking, nicotine dependence, and cessation failure.

128 antisocial personality disorder, alcoholism, nicotine dependence, and illicit drug abuse and dependen

129 Implications for conceptualizing risk for nicotine dependence, and its treatment, are discussed.

130 associated with increased smoking rate, high nicotine dependence, and low self-efficacy.

131 Hazards for alcohol dependence, nicotine dependence, and nondependent abuse of drugs or

132 that could be important in the treatment of nicotine dependence, and perhaps other neurological dise

133 ypes in the CNR1 gene may alter the risk for nicotine dependence, and the associations are likely sex

134 We apply this method to a GWAS of nicotine dependence, and use simulated data to test it o

135 Major depressive disorder (MDD) and nicotine dependence are highly comorbid, with studies sh

136 ecting risk for vulnerability to cocaine and nicotine dependence as well as bipolar disorder, suggest

137 CYP2A6 genotype is not associated with nicotine dependence, as defined by the Fagerstrom Test o

138 sk for lung cancer is direct or an effect of nicotine dependence, as evidence for both scenarios exis

139 datasets: the Collaborative Genetic Study of Nicotine Dependence (ascertained for tobacco use disorde

140 This can be used to prioritize nicotine dependence association studies through a straig

141 % with cannabis use disorder, and 56.6% with nicotine dependence at baseline.

142 4-77%) was associated with increased risk of nicotine dependence at P=3.7 x 10(-8) (odds ratio (OR)=1

143 quire replication, offer novel insights into nicotine dependence biology.

144 eased comorbidity with anxiety disorders and nicotine dependence but not alcohol dependence or bulimi

145 pregnancy are at elevated risk of developing nicotine dependence but not marijuana dependence as adul

146 ) have recently been shown to play a role in nicotine dependence, but it is not clear which nAChR sub

147 conduct an empirical study of progression of nicotine dependence by applying the WNA approach to thre

148 s analyzed in several brain areas related to nicotine dependence by immunofluorescence techniques.

149 rols, 45% female) treated in the Mayo Clinic Nicotine Dependence Center between 1988 and 2000.

150 vances in the understanding and treatment of nicotine dependence, close to 21% of adults in the Unite

151 vention involves a brief consultation with a nicotine dependence counselor.

152 nterest, and participant-reported ratings of nicotine dependence, craving, and self-efficacy were col

153 rt a genome-wide association study (GWAS) of nicotine dependence defined on the basis of scores on th

154 ndence, as defined by the Fagerstrom Test of Nicotine Dependence, demonstrating that cigarettes smoke

155 When analyses were further stratified by nicotine dependence, dependent smokers had higher CES-D

156 he primary eligibility criteria were current nicotine dependence (DSM criteria), smoking 10 or more c

157 daily smoking, progression to heavy smoking, nicotine dependence (Fagerstrom Test of Nicotine Depende

158 g smokers both with and without a history of nicotine dependence; for other outcomes, increases were

159 ine concentration (COT), Fagerstrom test for nicotine dependence (FTND) and schizophrenia to examine

160 or addiction by both the Fagerstrom Test for Nicotine Dependence (FTND) and the Revised Tolerance Que

161 metabolizers) had lower Fagerstrom Test for Nicotine Dependence (FTND) scores, suggesting lower leve

162 The Fagerstrom test for nicotine dependence (FTND) was used to assess dependence

163 sed with scores from the Fagerstrom Test for Nicotine Dependence (FTND).

164 measure for ND using the Fagerstrom Test for Nicotine Dependence (FTND).

165 analysis of items on the Fagerstrom Test for Nicotine Dependence gave evidence of three classes perti

166 recently the pre-eminence of this system in nicotine dependence has been challenged.

167 ing that cigarettes smoked per day (CPD) and nicotine dependence have distinct genetic correlates.

168 animal models that replicate key features of nicotine dependence have led to important advancements i

169 the involvement of alpha6 nAChR subunits in nicotine dependence have only recently emerged.

170 fluenced regulation in brain on the risks of nicotine dependence, heavy smoking and consequent lung c

171 derable evidence supports a genetic risk for nicotine dependence; however, less is known about the ph

172 four SNPs in the CHRNB2 gene with respect to nicotine dependence in a collection of 901 subjects (815

173 nd multiple measures of smoking behavior and nicotine dependence in a large, national representative

174 in CHRNB4 are associated with lower risk for nicotine dependence in African Americans and European Am

175 in the development and maintenance of strong nicotine dependence in cigarette smokers posit (i) a rap

176 A5) is the strongest genetic risk factor for nicotine dependence in European Americans and contribute

177 e basis of scores on the Fagerstrom Test for Nicotine Dependence in European-American (EA) and Africa

178 ale smokers but not in male smokers and with nicotine dependence in female but not in male smokers.

179 l signs, and has a protective effect against nicotine dependence in human genetic association studies

180 ggest potential utility for the treatment of nicotine dependence in humans.

181 ther investigation of R-MOD for treatment of nicotine dependence in humans.

182 AChR) family genes that are known to mediate nicotine dependence in mammals, suggesting functional co

183 pharmacotherapies for cognitive deficits and nicotine dependence in schizophrenia.

184 h was negatively associated with severity of nicotine dependence in slow metabolizers.

185 ses to other primary reinforcers that govern nicotine dependence in smokers.

186 ates, trends across cohorts, and the role of nicotine dependence in smoking persistence.

187 iants were associated with increased risk of nicotine dependence in the European American primary sam

188 We studied DSM-III-R nicotine dependence in the United States, trends across

189 ever, the role of rare variation in risk for nicotine dependence in these nicotinic receptor genes ha

190 or a significantly (P =.004) lower risk (for nicotine dependence, in the prospective data) in persons

191 ransition from smoking to the development of nicotine dependence, including an amino acid change in t

192 Nicotine dependence increased the risk of smoking persis

193 s, (1) whether the genetic predisposition of nicotine dependence influence COPD risk and lung functio

194 Nicotine dependence is a serious public health concern.

195 Nicotine dependence is influenced by chromosome 15q25.1

196 Nicotine dependence is one of the world's leading causes

197 Despite evidence that nicotine dependence is the leading preventable cause of

198 ine responses; however the role of CaMKIV in nicotine dependence is unknown.

199 elicit both the acute and chronic effects of nicotine dependence is unknown.

200 ajor depression, depressed mood at baseline, nicotine dependence level, or gender were observed.

201 cles of smoking and withdrawal contribute to nicotine dependence, long-term alterations in brain rewa

202 Ethnicity, weight, and level of nicotine dependence may help identify smokers who have g

203 nhanced understanding of these dimensions of nicotine dependence may help to advance progress toward

204 A modestly elevated risk for nicotine dependence might be an exception.

205 rsisted longer in smoking heavily, developed nicotine dependence more frequently, were more reliant o

206 6969968-A alleles together increased risk of nicotine dependence more than each variant alone: P = 3.

207 iew, we address these issues by developing a nicotine dependence (ND) genetic susceptibility map base

208 didate gene studies for smoking behavior and nicotine dependence (ND) have disclosed too few predispo

209 ne (GABAB2) were tested for association with nicotine dependence (ND) in an extensively phenotyped co

210 Nicotine dependence (ND) is a moderately heritable trait

211 ase (DDC) locus with the DSM-IV diagnosis of nicotine dependence (ND) or a quantitative measure for N

212 etic and environmental factors in regulating nicotine dependence (ND) risk, including the effects on

213 is an independent risk factor for offspring nicotine dependence (ND), but mechanisms remain unknown.

214 acetylcholine receptors (nAChR) subunits and nicotine dependence (ND), only few studies were performe

215 ccount for at least 50% of the liability for nicotine dependence (ND).

216 likely to harbor susceptibility gene(s) for nicotine dependence (ND).

217 een posttraumatic stress disorder (PTSD) and nicotine dependence (ND).

218 ement in the development of vulnerability to nicotine dependence (ND).

219 holine receptor subunits are associated with nicotine dependence (ND).

220 ificantly associated with the progression of nicotine dependence (ND).

221 study reported that NRXN1 is associated with nicotine dependence (ND); this, together with the intrig

222 The highest risk for nicotine dependence occurred in the first 16 years after

223 nomenon that is thought to contribute to the nicotine dependence of cigarette smokers.

224 ch in the neurobiologic and genetic basis of nicotine dependence offers promise for the development o

225 dissociation between the effects of chronic nicotine dependence on neural representations of reward

226 Furthermore, the effect of prior history of nicotine dependence on subsequent nicotine and alcohol t

227 ving a 2-fold increase in risk of developing nicotine dependence once exposed to cigarette smoking.

228 e to traumatic events increases the risk for nicotine dependence or alcohol or other drug use disorde

229 None of the trials assessed nicotine dependence or interest in quitting at any point

230 mprehensive, such as the Fagerstrom Test for Nicotine Dependence or the American Psychiatric Associat

231 to have a diagnosis of drug use disorder or nicotine dependence or to have used tobacco than their n

232 use disorder: OR, 2.6; 95% CI, 1.6-4.4; and nicotine dependence: OR, 1.7; 95% CI, 1.2-2.4), but not

233 applicable), cigarette consumption, level of nicotine dependence, other confounders, definition of qu

234 riers as assessed by the Fagerstrom Test for Nicotine Dependence (P=1.2 x 10(-4)).

235 sults may have relevance to acute stress and nicotine dependence, particularly in schizophrenic disor

236 t a biological level and are associated with nicotine dependence phenotypes.

237 nterdisciplinary approach to the genetics of nicotine dependence provides a model for testing how fun

238 u-opioid receptor (OPRM1) genotype, or their nicotine dependence questionnaire score (phenotype).

239 Participants with lower levels of nicotine dependence responded better than those with hig

240 Two behaviors central to nicotine dependence, reward and anxiety relief, were exa

241 Nicotine dependence risk and lung cancer risk are associ

242 ed differences in CHRNA5 mRNA expression and nicotine dependence risk to underlying DNA methylation d

243 her other CHRNA5 coding variation influences nicotine dependence risk, we performed targeted sequenci

244 g variants are independently associated with nicotine dependence risk.

245 , lower CHRNA5 mRNA expression and increased nicotine dependence risk.

246 ation studies, we provide evidence that both nicotine-dependence risk and lung cancer risk are influe

247 d number of cigarettes smoked per day, and a nicotine dependence scale.

248 d positively with higher Fagerstrom Test for Nicotine Dependence score (r = .58, p = .031) and more c

249 GWAS analysis considered Fagerstrom Test for Nicotine Dependence score as an ordinal trait, separatel

250 dary, quantitative phenotype, the Fagerstrom nicotine dependence score, that is correlated with COPD

251 with ND measured by the Fagerstrom Test for Nicotine Dependence score; of these, 11 SNPs remained si

252 icotine-dependent cases (Fagerstrom Test for Nicotine Dependence score4) and 1238 non-dependent contr

253 Finally, relationships with nicotine dependence scores showed enhanced response in i

254 In addition, individuals with greater nicotine dependence severity show increased engagement o

255 connectivity in 116 smokers with a range of nicotine dependence severity.

256 y and functional connectivity are related to nicotine dependence severity.

257 withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or

258 Severity of nicotine dependence significantly correlated with dopami

259 utcomes of smoking, as well as predictors of nicotine dependence, smoking initiation, and smoking ces

260 tempt, conduct disorder, alcohol dependence, nicotine dependence, social anxiety, rape after the age

261 hich have high prevalence rates of co-morbid nicotine dependence, stress-induced symptom exacerbation

262 ateralization of activation as a function of nicotine dependence suggests that chronic exposure to ni

263 of Cell, Feng et al. report a worm model of nicotine dependence that shows behavioral adaptations su

264 f the most powerful and extensive studies of nicotine dependence to date and has found novel risk loc

265 de association study (GWAS) meta-analysis of nicotine dependence, totaling 38,602 smokers (28,677 Eur

266 lack of consensus about the effectiveness of nicotine dependence treatment for cancer patients.

267 The results suggest that nicotine dependence treatment is effective for patients

268 Nicotine dependence treatment is imperative in such high

269 ng rate, number of recent quit attempts, and nicotine dependence; two key mediators of smoking cessat

270 new major depression following treatment for nicotine dependence was 2%, 17%, and 30% among subjects

271 Lifetime prevalence of nicotine dependence was 24%, nearly half of those who ha

272 The heritability of nicotine dependence was 60.3% (95% confidence interval [

273 We found the genetic predisposition of nicotine dependence was associated with COPD risk, even

274 Nicotine dependence was defined as smoking one's first c

275 Nicotine dependence was examined using logistic regressi

276 y smoking, number of cigarettes per day, and nicotine dependence was greater in females than in males

277 Nicotine dependence was measured by the Fagerstrom test

278 Nicotine dependence was measured by using the Fagerstrom

279 variation contributes to the development of nicotine dependence, we performed a comprehensive genome

280 nAChRs and/or cell types that play a role in nicotine dependence, we studied these receptors and cell

281 ver genetic variants that influence risk for nicotine dependence, we targeted over 300 candidate gene

282 The odds of progressing from smoking to nicotine dependence were almost twice as great for offsp

283 Rates of drug use disorders and nicotine dependence were also elevated compared with the

284 or 10 years on average, and met criteria for nicotine dependence were given SPECT scans on two days:

285 problem gambling and alcohol, cannabis, and nicotine dependence were obtained at age 21 years.

286 spring smoking behavior and lifetime risk of nicotine dependence were obtained by structured intervie

287 Nicotine dependence, which reduces the likelihood of qui

288 as Neurexin 1 (NRXN1), in the development of nicotine dependence while also identifying a known candi

289 Optimal treatment of nicotine dependence will require greater understanding o

290 and Negative Syndrome Scale (PANSS) and for nicotine dependence with the Fagerstrom Test for Nicotin